Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on August 24th, 2016 by Patrick C. May, PH.D.Pharma R&D
In a previous blog, I provided a few thoughts on tau-related drug discovery news coming out of the recent Alzheimer’s Association International Conference (AAIC16) in Toronto, Canada. In this post, I will highlight some of the research from the conference on gamma and beta-secretase, Continue reading “Review of Alzheimer’s Association International Conference (AAIC16) Part 2: Focus on Secretases” »
Posted on August 22nd, 2016 by Amram EwooPharma R&D
One of the strongest arguments for using the molecular biology modeling tool Pathway Studio is the rich content underlying its knowledge database. This was driven home recently in a conversation with the DNA/RNA sequencing company Illumina. Continue reading “Elsevier and Illumina: A meeting of mind and spirit” »
Posted on August 19th, 2016 by J.-P. Clement MDPharmacovigilance
Measuring the compliance of a defined set of variables is key for functions like pharmacovigilance, where there is intense reporting to different regulatory and non-regulatory entities with strict regulations and high inspection risk. Continue reading “Compliance Metrics for Pharmacovigilance Activities” »
Posted on August 17th, 2016 by Christine de Vries - ScheideggerPharma R&D
“Last year, Vice President Biden said that with a new moonshot, America can cure cancer. Last month, he worked with this Congress to give scientists at the National Institutes of Health the strongest resources that they’ve had in over a decade. So tonight, I’m announcing a new national effort to get it done,” said President Obama in his final State of the Union address in January 2016.
Posted on August 15th, 2016 by Patricia MorganPharma R&D
Product testing is a necessary step in almost any industry, but in the pharmaceutical world, testing the safety and efficacy of drugs isn’t just a matter of getting a few people to ‘try it out’ – it’s a massive, tightly-regulated effort requiring extensive drug trials that include hundreds or thousands of participants. Continue reading “Reaching Out to Potential Drug Trial Participants” »
Posted on August 12th, 2016 by Jeffrey Paul, PhDPharma R&D
The future is biomarkers. This is an often-cited phrase you will have heard at drug development symposia and printed in articles. The line reminds me of the film, The Graduate, where Mr. McGuire tells young Benjamin that there is a “great future in in plastics.” Biomarkers are the plastics for personalized medicine, Continue reading “The Many Shapes and Colors of Biomarkers” »
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.